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ComorbiditiesSeizures in some 30% to 40% of patients with epilepsy fail to respond to antiepileptic drugs or other treatments.
Whilemuchhas beenmade of the risks of newdrug therapies, not enough attention has been given to the risks of
uncontrolled and progressive epilepsy. This critical review summarizes known risks associated with refractory
epilepsy, provides practical clinical recommendations, and indicates areas for future research. Eight international
epilepsy experts from Europe, the United States, and South America met on May 4, 2013, to present, review, and
discuss relevant concepts, data, and literature on the consequences of refractory epilepsy.While patientswith re-
fractory epilepsy represent theminority of the populationwith epilepsy, they require the overwhelmingmajority
of time, effort, and focus from treating physicians. They also represent the greatest economic and psychosocial
burdens. Diagnostic procedures and medical/surgical treatments are not without risks. Overlooked, however, is
that these risks are usually smaller than the risks of long-term, uncontrolled seizures. Refractory epilepsy may
be progressive, carrying risks of structural damage to the brain and nervous system, comorbidities (osteoporosis,
fractures), and increased mortality (from suicide, accidents, sudden unexpected death in epilepsy, pneumonia,
vascular disease), as well as psychological (depression, anxiety), educational, social (stigma, driving), and voca-
tional consequences. Adding to this burden is neuropsychiatric impairment caused by underlying epileptogenic
processes (“essential comorbidities”), which appears to be independent of the effects of ongoing seizures them-
selves. Tolerating persistent seizures or chronic medicinal adverse effects has risks and consequences that often
outweigh risks of seemingly “more aggressive” treatments. Future research should focus not only on controlling
seizures but also on preventing these consequences.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).1. Risks of refractory or uncontrolled epilepsy
More than 50 million people worldwide suffer from epilepsy [1].
Each year, 16 to 134 new-onset epilepsy cases per 100,000 people add
to the global burden of epilepsy [2,3]. In a population-based study con-
ducted in Western Europe, the epilepsy in 22.5% of all patients wasram, California Paciﬁc Medical
94115, USA. Tel.: +1 415 600
00 7885.
.
. This is an open access article underfound to be drug-resistant [4]. Patients with drug-resistant epilepsy ac-
count formost of the burden of epilepsy in the population [5] because of
the substantial frequencies atwhich they experience comorbid illnesses
[6,7], psychological dysfunction [8], social stigmatization [9], reduced
quality of life and increased risk of mortality [10–12], and, ultimately,
a decreased life expectancy [6,13]. Therefore, treatment efforts must
aim for full seizure control, especially for generalized tonic–clonic sei-
zures. Diagnostic procedures and medical and surgical treatments are
not without their own risks [14–19]. However, these risks are usually
smaller than the risks of uncontrolled, progressive, or drug-resistant
epilepsy. Moreover, these risks must be explained to patients carefully,
such that informed treatment decisions can be made.the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/3.0/).
Fig. 1. Cumulative rate of death according to cause of epilepsy.
Copyright © 2010 N Engl J Med. Reproduced with permission from
Massachusetts Medical Society.
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The incidence of epilepsy in developed countries is approximately
50 per 100,000 individuals per year, with the greatest rates for infants
and the elderly [2,20]. In developing and resource-poor countries,
where most people do not receive adequate treatment, the incidence
is usually greater than 100 per 100,000 individuals per year [2,21]. A de-
cline in the incidence of childhood epilepsy has been observed during
the past 30 years in developed countries, but this has been paralleled
by an increase in the incidence of epilepsy in the elderly [22,23]. The
prevalence of epilepsy in developed countries ranges between 4 and
10 per 1,000 individuals per year [2,20,21], with much greater preva-
lence rates in developing and resource-poor countries [2], and some es-
timates at greater than 130 per 1000 individuals per year [3,24].
The seizures in approximately two-thirds of people with epilepsy
can be successfully controlled with currently available antiepileptic
drugs (AEDs), leaving one-third with uncontrolled epilepsy [25]. The
temporal patterns of epilepsy, with a substantial number of patients
following a relapsing–remitting course [26,27], can render early identi-
ﬁcation of patients with drug-resistant epilepsy a difﬁcult task and may
explain delays in referrals to epilepsy surgery centers [28,29]. Although
up to 24% of patients with drug-resistant epilepsy can achieve remis-
sions for more than 1 year [30–33], physicians should not withhold re-
ferral for presurgical evaluation, since two randomized controlled
studies have clearly shown superiority of surgical treatment versus con-
tinuous medical treatment [34,35]. Based on these studies, the number
of patients with temporal lobectomy needed to treat to render one
patient completely seizure-free after years of chronic disabling seizures
is b2 [34,35]. A delay in referral increases the burden of epilepsy for the
overall population, and reduces life spans and quality of life for individ-
ual patients.
1.2. Drug resistance and its clinical predictors
In 2010, the International League Against Epilepsy published a
consensus deﬁnition of drug-resistant epilepsy that aimed to improve
patient care and facilitate research, and which should ultimately lead
to earlier identiﬁcation of and better delineation of the syndromes asso-
ciated with drug resistance [36]. The deﬁnition of drug resistance en-
compasses two hierarchical levels. Level 1 provides a general scheme
to categorize response to interventions as seizure freedom, treatment
failure, or undetermined, on the basis of standard criteria. Level 1 pro-
vides the basis for Level 2 determinations, which form the core deﬁni-
tion of drug-resistant epilepsy “as a failure of at least two tolerated,
appropriately chosen and used” AED regimens “to achieve sustained
freedomof seizures [36].”According to the “rule of three” for calculating
conﬁdence intervals for zero events [37], “sustained seizure freedom”
requires that the patient be seizure-free for at least three-times the
longest interseizure interval before the intervention, or at least
12 months, whichever is greater [36]. This deﬁnition conceptualizes
drug resistance as a dynamic phenomenon, also allowing for remission
over time [26], which can be observed at an annual rate of 4% for adults
in prospective series and at even greater rates for children [38–40].
Besides the number of failed AEDs (which is used as a deﬁnition
criterion), the most consistent predictors of refractory epilepsy are a
high frequency of seizures in the early phase of the disease, a neurologic
deﬁcit at disease onset, and a structural cause of the epilepsy, as evi-
denced by MRI [39,41–43]. However, uncontrolled epilepsy is not
always drug-resistant [44], and pseudoresistance due to incorrect diag-
nosis, inappropriate AED, or inappropriate dosage must be ruled out
before a patient's seizures can be considered drug-resistant [45–50].
1.3. Burden of refractory epilepsy
The impact of epilepsy on an individual's life is a combination of
physical consequences of seizures, effects on social position, andpsychological outcomes of both. An estimated 26% of the burden of neu-
rologic disorders is caused by epilepsy, calculated in disability-adjusted
life-years (DALYs) [51]. In 2011, the global burden of chronic epilepsy
for women was greater than that of breast cancer, and was nearly
four-times greater than the burden of prostate cancer for men [51].
This calculation includes premature deaths and the loss of healthy life
because of disability. However, it does not factor the effects of stigma
and social exclusion or their repercussions on families [9,52].2. Epilepsy and mortality
Mortality is greater for those with epilepsy than for those without
for many reasons, including sudden unexpected death in epilepsy
(SUDEP), accidents, suicide, vascular disease, pneumonia, and factors
directly related to the underlying causes (e.g., brain tumors, neurode-
generative disease). Within epilepsy, mortality is greatest for those
with refractory disease. Although this excess mortality has been long-
recognized, many large, high-quality studies (all published in 2013)
have provided important details about the magnitude of the problem,
consistent ﬁndings between countries, and speciﬁc causes [12,53–61].
Overall, peoplewith epilepsy have a 1.6- to 11.4-times greatermortality
rate than expected [55,56,62]. In childhood-onset epilepsy, the stan-
dardized mortality ratio (SMR) is 5.3–9.0 [59,63,64]. In a study of 245
children with epilepsy in Finland followed for 40 years, 24% had died
(3 times the expected rate) [64]. Cumulative mortality was 37% for
those with symptomatic epilepsy and 12% for those with idiopathic/
cryptogenic epilepsy (Fig. 1) [64]. Of the 107 patients not in terminal re-
mission (i.e., not seizure-free for the last 5 years), 48% had died. The
only multivariate predictor of survival was 5-year terminal remission
of seizures [64].
In an older study of 564 newly diagnosed patients from the United
Kingdom, those with symptomatic epilepsy had up to a 10-year shorter
life expectancy than those without epilepsy [6]. Further, those with
epilepsy of unknown cause had up to a 2-year shorter life expectancy
[6]. A later follow up of the same cohort for 20 to 25 years found a
SMR of 2.55 overall, with a 3.68 SMR (3.05–4.42) for those with symp-
tomatic epilepsy, and a 1.66 SMR (1.33–2.06) for those with idiopathic/
cryptogenic epilepsy [65]. These SMRs remained signiﬁcantly increased
20 to 25 years after diagnosis, despite greater than70% of patients being
in remission. In a very large study of 69,995 people with epilepsy
in Sweden followed for an average of 9 years, 8.8% had died, with a
median age of 34.5 years at time of death. The adjusted odds ratio for
mortality was 11.1 versus the general population and 11.4 compared
with unaffected siblings (Table 1) [55].
Table 1
Risks of premature death in individuals with epilepsy compared with those in population
controls and unaffected siblings.
Copyright© 2013 Lancet. Reproducedwith permission to be obtained fromElsevier Inc. [55].
Odds ratio for death
compared with
population controls
(aOR [95% CI])
Odds ratio for death
compared with
unaffected sibling controls
(aOR [95% CI])
All-cause mortality 11.1 (10.6–11.6) 11.4 (10.4–12.5)
Natural causes 15.5 (14.6–16.4) 16.7 (14.9–18.7)
Neoplasms 11.2 (10.3–12.2) 11.3 (9.4–13.7)
Nervous system 71.1 (57.3–88.4) 86.9 (54.3–139.1)
External causes 3.6 (3.3–4.0) 3.2 (2.7–3.7)
Suicide 3.7 (3.3–4.2) 2.9 (2.4–3.6)
All accidents 3.6 (3.1–4.1) 3.6 (2.9–4.5)
Vehicle 1.4 (1.1–1.8) 1.5 (1.1–2.2)
Other 5.5 (4.7–6.5) 6.3 (4.6–8.8)
Drug poisoning 5.1 (3.9–6.5) 5.7 (3.3–9.7)
Fall 8.5 (5.3–13.7) 10.0 (2.9–33.8)
Drowning 7.7 (4.7–12.7) 9.5 (3.5–25.7)
Other and unspeciﬁed 4.9 (3.6–6.5) 5.2 (3.2–8.5)
Assault 2.8 (1.6–4.8) 1.7 (0.9–3.3)
Data are adjusted odds ratios (aOR) of external deaths comparedwith population controls
(matched for age and sex, and adjusted for income, andmarital and immigration status) or
unaffected sibling controls (adjusted for age and sex).
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In a 30-year cohort study of 3334 outpatientswith epilepsy in Austria
[12], the most common cause of death was non-CNS malignancies,
followed by cardiovascular and cerebrovascular diseases. In addition,
9% had died from external causes (e.g., accidents, drowning, injury),
and 7% had died from epilepsy (i.e., SUDEP or status epilepticus [SE])
[12]. In the large Swedish study mentioned above [55], the most com-
mon causes were neoplasms and central nervous system diseases,
followed by external causes (e.g., suicide, accidents, or assault — 16%
of all deaths). The SMRs were greater than those for the general popu-
lation and sibling controls for all of these causes, including a SMR of 6.3
compared with siblings for nonvehicular accidents, 2.9 for suicide (N20
if comorbid depression or substance misuse), 9.5 for drowning, and 5.7
for drug poisoning. The SMR for vehicular accidents was only slightly
elevated at 1.5. The authors noted that 75% of those who had died
from external causes had psychiatric comorbidities, especially depres-
sion and substance abuse. In the U.K. cohort [65], the leading causes
of death were neoplasms (mostly non-CNS), pneumonia, and cardio-
vascular and cerebrovascular diseases. The SMRs for all these causes
remained increased throughout the 20- to 25-year follow up [65]. The
SMR for pneumonia was particularly high (7.9) [65]. In the Finnish
study of childhood-onset epilepsy [64], 55% of deaths were epilepsy-
related (30% to 38% with SUDEP, 10% with drowning), 20% were from
pneumonia, 13% were from cardiovascular disease, and 3% were from
suicide [64].
Other studies have conﬁrmed that epilepsy is associated with great-
er rates of both cardiovascular and cerebrovascular diseases [62,66];
substance abuse, which increases the SMR even further [62,67]; com-
pleted suicide (SMR of 3.3, though much greater with psychiatric
comorbidities) [68,69]; and accidents (SMR of ~5) [62,70]. A meta-
analysis concluded that drowning is 15- to 19-times more common
for those with epilepsy than for the general population and may be re-
sponsible for up to 5% of deaths for people with epilepsy [71].2.2. Sudden unexpected death in epilepsy
Sudden unexpected death in epilepsy is deﬁned as “sudden, unex-
pected, witnessed or unwitnessed, nontraumatic, and nondrowning
death, occurring in benign circumstances, in an individual with epilepsy,
with or without evidence of a preceding seizure and excludingdocumented status epilepticus [72].”Deﬁnite SUDEP requires a postmor-
tem examination that does not reveal an alternative cause of death. If no
postmortem examination is performed, the cause is designated “proba-
ble SUDEP” [72]. The average incidence is 1 per 1,000 patients with epi-
lepsy per year. In refractory epilepsy, the incidence is 6 per 1,000 patients
per year, and the lifetime incidence is 7% to 35%, with the greater end of
this range applying to childhood-onset refractory epilepsy [73]. Risk of
sudden, unexplained death in those with epilepsy is approximately 16-
times that of the general population, after adjustment for multiple
factors, including age, sex, and psychiatric and neurologic disease [56].
Sudden unexpected death in epilepsy is most common in young adults,
followed by adolescents. Approximately 2000 SUDEP deaths occur each
year in the United States [73]. The estimate of “years of potential life
lost” to SUDEP is 73,000 per year in the United States, greater than the
values formultiple sclerosis, Alzheimer's disease, and Parkinson's disease
[73].
Having uncontrolled seizures, especially convulsive and nocturnal
seizures, is the greatest risk factor for SUDEP [74–77]. However,
SUDEPhas occurred in patientswith seeminglywell-controlled epilepsy
(rare) and in those who had never had a convulsion (a signiﬁcant
minority of cases). For example, 20% of more than 150 patients who
suffered from SUDEP had no history of convulsive seizures in one
study [78]. In an older study of 20 SUDEP cases, 4 had no known convul-
sions in the prior year, and 2 had been reportedly seizure-free [79].
Approximately 80% of witnessed or recorded SUDEP cases are asso-
ciated with seizures. Although earlier studies had suggested that
polytherapy or speciﬁc medications were associated with SUDEP, this
does not appear to be the case (with controlling for frequency of convul-
sions) [80,81]. In fact, adding an AED to therapy rather than placebo
appears to lower the rate of SUDEP, at least in the short term, based
on a meta-analysis of 112 randomized controlled trials of AEDs [82]. In
that meta-analysis, the rate of SUDEP was 0.9 per 1,000-patient-years
in the active AED arm vs. 6.9 in the placebo arm (odds ratio of 0.17 for
SUDEP, p = 0.005, and odds ratio of 0.37 for all mortality). In addition,
a study employing Medicaid claims data for 33,658 patients found that
periods of nonadherence to AEDs were associated with a tripling of
mortality, as well as increases in emergency department visits, motor
vehicle accidents, fractures, and hospitalizations [83].
2.3. Causes of SUDEP
In most witnessed or recorded cases, respiratory issues appear to
precede cardiac arrhythmias. Hypoxemia, mainly associated with cen-
tral apnea, occurs with many seizures, and not just generalized convul-
sions. In one investigation, 35% of focal seizures without secondary
generalization were associated with oxygen saturation below 90%, and
11% of these seizures fell below 80% [84]. Serotonin deﬁciency may
play a role in periictal apnea as has been found in sudden infant death
syndrome [85,86]. In an animal model of SUDEP, boosting serotonin
concentrations prevented seizure-related apnea and death [87,88].
Generalized EEG suppression, or “central shutdown,” may also occur
early. In one study, duration of postictal EEG suppression was strongly
correlated with risk of SUDEP [89], but this was not found in another
study [90]. Many cardiac and autonomic changes have been discovered
in ictal and postictal settings. Recent data suggest that genes associated
with ion channels expressed in both the heart and brainmay predispose
to seizure-related cardiac arrhythmias, andmay be part of the combina-
tion of factors necessary to lead to SUDEP [91]. Other contributing
factors may include acidosis, the prone position, rebreathing of CO2,
excessive adenosine or opioids, spreading depression, or laryngospasm
[74–76,92–96].
An important recently published international study (MORTEMUS
[97]) on mortality in epilepsy monitoring units (EMUs) identiﬁed 16
cases of SUDEP and 9 cases of near-SUDEP (successfully resuscitated)
at 148 EMUs, mostly in Europe [97]. Fourteen of the 16 SUDEP cases
occurred at night, and most patients were not directly supervised at
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prone position, and all were preceded by a convulsive seizure. Seven
of the 9 near-SUDEP cases also followed a convulsion. All successful re-
suscitations began within 3 minutes of arrest, whereas all unsuccessful
ones began after at least 10 minutes [97]. In the 10 cases with adequate
cardiac, respiratory, and video monitoring, a consistent but complex
pattern was detected consisting of postictal tachypnea, followed by an
early, centrally mediated, parallel collapse of both cardiac function and
respiratory function within 3 minutes postictally [97]. This was termi-
nal in one-third of the cases, but transient recovery occurred in the
rest. In the cases with transient recovery, gradual failure of respiration
developed, with terminal apnea always preceding terminal asystole
[97].
2.4. SUDEP prevention
Maximizing seizure control is the only provenmethod of decreasing
the risk of SUDEP. Besides the evidence for this method observed in
studies on medication noncompliance and the placebo arms of the
AED studies described above, additional supporting evidence comes
from several studies demonstrating that SUDEP risk for those rendered
seizure-free after epilepsy surgery is markedly decreased [76,98–102].
However, the evidence that surgery itself is what lowered the risk is
not deﬁnitive, as these datawere not from randomized trials, and intrin-
sic differences in SUDEP risk between patients amenable to surgical cure
and those who are not may confound the results.
Nocturnal supervision appears to be protective-based on three stud-
ies: MORTEMUS [97], during which most deaths in EMUs occurred at
night with inadequate supervision (by medical staff in this case); a
case-controlled study showing a reduced risk of SUDEP with nighttime
supervision (room sharing or listening device) [78]; and a study of chil-
dren with severe epilepsy living in a residential school, with all 14
deaths occurring during breaks outside the school, rather than when
children were closely supervised in school [103]. Most of these deaths
were unwitnessed. Discussing the risk of SUDEP with patients and fam-
ilies is strongly recommended for virtually all people with epilepsy, as it
will likely help patientsmaximize compliance and avoid seizure triggers
such as sleep deprivation and alcohol use. Seizure alarms are beginning
to be investigated scientiﬁcally, with technical improvements and
further data likely to emerge quickly [74,104,105]. Rapid advances in
SUDEP research should help elucidate risk factors, mechanisms, and
other preventive strategies.
3. Epilepsy as a progressive disorder
Epilepsy progression may be considered the worsening over time of
seizure control, cognition, behavior, structural abnormalities, EEG
patterns, or social interactions in patients who do not have underlying
progressive brain disorders. This is a controversial area, with evidence
for and against epilepsy as a progressive disease. The heterogeneity
and difﬁculties in classifying seizures and different forms of epilepsy
[106], and in characterizing resistance to AEDs [36,43,107], are addition-
al obstacles to deﬁning when and how epilepsy progression occurs [27,
108–111].
Some types of epilepsy progress over time [112,113], while others
most likely do not (e.g., childhood absence and juvenile myoclonic epi-
lepsies [106,114,115]). However, high-seizure frequenciesmay be relat-
ed to worse social adjustment outcomes [116]. In addition, one study of
patients with idiopathic generalized epilepsies with only tonic–clonic
seizures found that reductions of thalamic volumes and fronto-central
and limbic cortices occurred faster in patients with poorer seizure
control [117]. It is unclear if the progression of damage with some
focal epilepsies depends on underlying etiologies, prolonged focal sei-
zures, frequencies of secondary generalized seizures, durations and fre-
quencies of focal seizures, genetic predisposition, other environmental
factors (e.g., viral infections, head trauma), or a combination of thesefactors [111,118–124]. Whether some epilepsy syndromes are progres-
sive but not medically refractory is still unclear. However, preliminary
evidence indicates that, in the context of familial mesial temporal lobe
epilepsy (TLE), patients experience hippocampal volume reductions
over time independent of seizure frequency [125]. Furthermore, struc-
tural and functional damage occurs in patients achieving good response
to AEDs [126], and in patients with new-onset TLE [127].
3.1. Neuroimaging and structural damages
Evidence that some types of epilepsy do progress over time is de-
rived from neuroimaging studies. Different studies have demonstrated
structural damage to be more pronounced in individuals with longer
durations of epilepsy, and others have been able to quantify this pro-
gression over time. However, other studies have failed to demonstrate
progression, possibly because of the heterogeneity of the individuals
evaluated [109].
Neuroimaging studies have shown widespread extrahippocampal
neuronal damage and dysfunction in patients with mesial TLE with
and without hippocampal sclerosis [124,128–132]. This damage pro-
gresses over time [133–138] and improves after successful surgical
treatment [139–141]. However, it is still unclear why, when, and how
brain damage occurs in TLE. Seizure frequency is considered the most
important factor for progression in mesial TLE. However, it is possible
that not all types of seizures induce damage, or that some individuals
are more resistant to seizure-induced damage [136,142,143]. Genetic
background, age, type of initial brain insult, and other environmental
factors most likely interact in several ways, making it difﬁcult to deter-
mine the underlying mechanisms of damage progression in TLE [136].
Mechanisms responsible for or that inﬂuence the development of
chronic epilepsy differ from those that actually precipitate acute epilep-
tic seizures [108]. Another variable is that seizure-related damage may
be expressed in many ways, and does not necessarily represent neuro-
nal loss or atrophy. For example, patients with mesial TLE often have
progressive memory loss and, sometimes, cognitive impairment, as
well as progressive increases of bilateral epileptiform discharges on
EEG [112,113,142,144–149]. These observations suggest that focal epi-
lepsy may lead to neuronal dysfunction remote from the seizure foci.
3.2. “Seizures beget seizures”
The concept introduced byDr.WilliamGowers (1881) that “seizures
beget seizures” indicates the implicit concept that epilepsy may be a
progressive disorder related to the occurrence of seizures [150]. Since
then, or maybe even before, the “cause-or-consequence” issue of
repeated seizures and brain damage (and, more speciﬁcally, hippocam-
pal sclerosis in TLE) has been debated [111,142,151–155].
Descriptions of SE leading to neuronal changes in rats and humans
abound, especially in the hippocampus, which clearly indicate that sei-
zures in the context of SE can cause hippocampal sclerosis and further
TLE [111,156–159]. However, there is also evidence for the occurrence
ofMRI signs of hippocampal sclerosis in peoplewithout epilepsy or pre-
ceding the onset of seizures, clearly indicating a strong genetic inﬂuence
in the development of hippocampal sclerosis [160–162].
The 1954Meyer's hypothesis [163,164] that hippocampal sclerosis is
both a cause as well as a consequence of epileptic seizures in TLE has
been supported by more recent investigations [153,165]. By expanding
the concept of initial precipitating injury (IPI) to include any signiﬁcant
medical event likely to injure the brain before the onset of epilepsy, such
as prolonged focal seizures, trauma, hypoxia, and intracranial infection,
studies of surgical series of mesial TLE have found a strong association
between hippocampal sclerosis and IPI [153]. These studies support
the concept that hippocampal sclerosis is likely an acquired pathology,
andmost of the neuronal loss occurswith the IPI. However, ongoing fre-
quent seizures do cause additional progressive hippocampal damage
[133–135,137,138,153,166].
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frequency on progressive epilepsy damage is reliance on patients' and
observers' accounts, which are well-known to be inaccurate [166]. In
addition, many patients have seizures that go unnoticed or are not
remembered, particularly in TLE.
Another chicken-or-the-egg dilemma is whether more extensive
structural damage induced by IPI causes more frequent seizures or
more frequent seizures cause more widespread damage [124,167].
Patients with refractory epilepsy seem to have frequent seizures from
the beginning of their epilepsies, have seizures that fail to respond to
AEDs early in their disease courses, and may have widespread damage
from onset of epilepsy [27,43,124,127]. In contrast, patients with good
response to AEDs tend to have well-controlled seizures and perhaps
even achieve remission [126,163,167].
Some studies support the hypothesis that generalized seizures and
not focal seizures are the main cause of progressive damage [122,168].
In contrast, some community-based studies or other studies with very
heterogeneous groups of individuals failed to associate seizures with
further injury in individuals with epilepsy [151,169,170]. This suggests
that most of the brain damage occurs before the onset of seizures or
develops insidiously over a more prolonged period [121].
3.3. Duration of epilepsy
Duration of epilepsy, independent of seizure frequency, has also
been associated with epilepsy progression, in the region of putative
seizure onset [171,172] and in remote areas [137,172]. Earlier age of
epilepsy onset has also been related to worsening of structural damage
in TLE [172,173], as well as to an adverse neurodevelopmental impact
on brain structure and function [173].
3.4. Epilepsy progression and response to antiepileptic drugs
Community-based studies of patients with several years of delay
before starting AED therapy show patterns of response similar to
those for patients with newly diagnosed epilepsies [174,175].
The inﬂuence of AED exposure in epilepsy progression is also not
well-understood. One study [169] showed generalized brain atrophy
more commonly in patients with increased exposure to AEDs, indepen-
dent of seizure control. However, no large conclusive data set investi-
gating the different types and mechanisms of various AEDs has been
published, rendering this a difﬁcult issue to address. The majority of in-
dividuals with refractory epilepsies (i.e., those more susceptible to epi-
lepsy progression) are exposed to greater dosages/regimens of AEDs,
compared with those with good seizure control (i.e., those less suscep-
tible to damage progression also tend to receive lesser AED dosages, and
less frequently receive polytherapy). Therefore, with the relationship
between widespread brain damage (at least in part, preceding seizure
onset) and high frequency of seizures, one of the best prognostic factors
appears to be response to the ﬁrst AED tried. Approximately 60% of pa-
tients with epilepsy will become seizure-free with the ﬁrst one to two
AEDs, and approximately 4% with further AED trials [43].
Despite the controversial views of the results of different studies
(Table 2) — which may be related to the heterogeneity of the patients
included —most current evidence indicates that TLE is often a progres-
sive disorder. In this context, for patients with refractory seizures, resis-
tance to AEDs must be deﬁned early, and surgery or other alternativeTable 2
Natural history of epilepsies: controversies.
Progressive [148,176]
• Tendency toward progressive reduction of seizure-free intervals in populations without treatm
• Worse prognosis of seizure control related to the number of seizures prior to treatmenttreatments must be considered as soon as possible. Early control of
seizures may decrease the risk of progressive structural, cognitive, and
behavioral damage related to repeated seizures.
Secondary epileptogenesis is the concept that an initial seizure focus
over time can generate a secondary focus that, with additional seizures
and time, will become independent of the initial focus. Secondary
epileptogenesis is readily demonstrated in animals by kindling [177,
178], but its presence in humans is controversial. Morrell [149,179]
studied a series of patients with tumor-related epilepsy and found clin-
ical, EEG, and/or pharmacologic evidence of secondary epileptogenesis
in 34% of these patients. Unlike epilepsy secondary to trauma, infection,
or vascular disease, tumors present an etiology for which the develop-
ment of additional ictal fociwould be highly unlikely.Morrell concluded
that the more frequent the seizures and the longer the epilepsy dura-
tion, the more likely a secondary focus would be to become permanent
and independent of the initial inciting focus [149,179]. This is in keeping
with the observation that bitemporal spiking occurs frequently in
patients with unilateral temporal-lobe seizure onsets [180]. However,
the contralateral spikes tend to decrease or disappear after successful
surgery [181].
The data on the “pros” and “cons” of the progression of damage in
epilepsy presented above clearly indicate that the issue is complex
and heterogeneous and needs to be examined further in more homoge-
neous groups of patients. Therefore, until we have more robust evi-
dence, it is up to readers to decide whether epilepsy is a progressive
disorder or not on the basis of the available data and the readers' own
judgments.
4. Neuropsychiatric comorbidities of refractory epilepsy: the
chicken or the egg?
As the foregoing sections suggest, most of themortality andmorbid-
ity of epilepsy is borne by patients with chronic refractory seizures.
Therefore, it has often been assumed that seizure activity itself is thepri-
mary cause of the cognitive, emotional, and behavioral comorbidities
that commonly occur. The extensive literature on the topic, going back
many decades, shows that patients with chronic seizures experience
greater rates of cognitive deﬁcits, emotional problems, physical and
psychiatric disease, health care utilization, educational and occupational
underachievement, failure in fulﬁlling normal social roles, and reduced
quality of life [115,182–191]. Many psychosocial problems improve
when chronic seizures remit [34,35,192–194]. For example, 31% of
young adults in one longitudinal cohort continued to have seizures
15 years after diagnosis. Approximately 45% of these were employed,
compared with approximately 88% of patients who had been in remis-
sion at least 5 years [192]. It is, therefore, not surprising that efforts to
understand and treat comorbidities have historically focused on deter-
mining the mechanisms by which seizures become refractory and de-
veloping treatments to suppress them.
However, it is increasingly apparent that the effects of refractory
epilepsy go beyond the effects of seizures themselves. A growing body
of literature suggests a more complex set of causal relationships than
has previously been considered. In a nutshell, it is increasingly clear
that neuropsychiatric comorbidities are evident prior to the onset of
observable seizure activity, or sufﬁciently soon after onset that they
are unlikely to have been caused by seizure activity itself. They, there-
fore, are likely to reﬂect pre-existing, otherwise “clinically silent,”Not progressive [108,175]
ent • Untreated population: no unfavorable evolution
• Tendency of worsening over time related to inherent severity of the disease
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cal seizure foci.
Epidemiologic studies have provided the ﬁrst clues that comorbidi-
ties can precede the onset of seizures. In two large, independent popu-
lation cohorts followed prospectively, those who ultimately developed
idiopathic or cryptogenic epilepsy weremore likely than controls with-
out epilepsy to have had prior diagnoses of the inattentive type of
ADHD, depression, and suicide attempts [195–197]. Because these
studies were limited to idiopathic (presumed genetic) or cryptogenic
(presumed developmental) cases, the associations cannot be explained
by pre-existing (e.g., remote-symptomatic) neurologic insults. Develop-
mental, stress-related, hypothalamic–pituitary–adrenal axis dysfunc-
tion and associated abnormalities in hippocampal neurogenesis and
cell death may underlie the comorbidity of some forms of refractory
epilepsy and depression [198]. Of childrenwith idiopathic or cryptogen-
ic epilepsy who had received special education services in a longitudi-
nal, population-based study, 31% had begun receiving services before
the onset of clinical seizures [188].
Studies of recently diagnosed patients are necessarily confounded by
retrospective assessment, medications, and recent seizures. Neverthe-
less, they provide the best estimates of antecedent functional and struc-
tural deﬁcits in the absence of large prospective studies of at-risk
persons. Children with ﬁrst-recognized seizures were 2.8-times more
likely than their siblings to be perceived by their parents as having
had clinically signiﬁcant attention problems in the preceding 6 months
[199]. Cognitive deﬁcits compared with those of controls have been
evident within 3 to 12 months of diagnosis, even in nonmedicated pa-
tients [200–202]. Children diagnosed with localization-related epilepsy
within the previous year had greater cortical gray-matter volumes in
various brain regions compared with cousin controls [173]. Children
with idiopathic generalized epilepsies had greater gray-matter and less-
er white-matter tissue volumes throughout the frontal, parietal, and
temporal regions, including subcortical structures with lesser gray-
matter tissue volumes in the medial orbitofrontal region [173].
Although these ﬁndings suggest that structural and functional ab-
normalities often precede the onset of seizures and medication use,
they remain inconclusive. Stronger evidence for antecedent functional
and structural abnormalities could come from studies of unaffected pro-
bands in highly familial forms of epilepsy. For example, frontothalamic
networks that support executive function are deﬁcient in juvenile myo-
clonic epilepsy [203]. Unaffected siblings of these patients performed
better on a task of executive function than probands, but performed
worse than unrelated healthy controls [204].
In summary, persisting seizures place a large psychosocial burden on
patients, families, and society. However, many “essential comorbidities”
precede seizure onset and the refractory state in “epilepsy-only” pa-
tients (Table 3), account for many psychosocial consequences, and
may persist even when seizures become controlled. In light of these
new studies, it is important to consider that refractory seizures are
just one of a number of signs and symptoms of a heterogeneous set of
genetic, developmental, and acquired refractory epilepsy syndromes.
At the basic scientiﬁc level, this implies that epileptogenic processes
may share common vulnerabilities and etiologic processes with theseTable 3
Comorbidities precede seizure onset in “epilepsy-only” patients.
• Idiopathic and cryptogenic epilepsies
• Otherwise neurologically “normal,” based on the following:
– Exam
– Intelligence
– Imaging
– History
• Greater degrees of the following are evident at, before, or soon after onset of seizures
– ADHD, depression [199–201]
– Behavioral problems [114]
– Special education [188]
– Cognitive difﬁculties [152,205]comorbid conditions. At a clinical level, it implies that the aimof “no sei-
zures, no adverse effects” is a necessary but insufﬁcient waypoint
toward the goal of signiﬁcantly improving the quality of life of those
with refractory epilepsy. Therefore, concepts of aggressive treatment
must take a broader scope by incorporating early diagnosis and treat-
ment of comorbidities.
5. Risks of antiepileptic drug treatment
Patients with chronic epilepsy usually require long-term treatment
with AEDs, and those with refractory epilepsy often receive
polytherapy. Potential treatment outcomes and subsequent decisions
are outlined in Fig. 2 [205]. Adverse effects of AEDs have been reviewed
in detail elsewhere [206–208]. In general, the adverse effects of AEDs
can be divided into the following categories: (1) dosage-related for
that individual patient (There is considerable overlap of central nervous
system adverse effects characterized by lethargy, dizziness, and behav-
ioral and cognitive impairment. These symptoms are mostly dosage-
related and are more prevalent with certain AEDs [e.g., topiramate:
word-ﬁnding difﬁculties and confusion, and levetiracetam: behavioral
changes]); (2) hypersensitivity reactions, usually within 2 to 3 months
of initiating a speciﬁc agent for many AEDs, but speciﬁc guidelines for
use (age, coadministration, and dosage-increase rate) have obviated
the occurrence in many patients; (3) long-term adverse events (e.g.,
cerebellar atrophy, retinal dysfunction, aplastic anemia, and lympho-
ma), greater awareness of which has led physicians to switch to AEDs
with more favorable long-term safety proﬁles; (4) adverse drug–drug
interactions, which are much more common with ﬁrst-generation
AEDs; (5) long-term, adverse hormonal and metabolic adverse effects
related to use of P450-inducing agents (e.g., exacerbation of osteoporo-
sis and acceleration of vascular disease) [209]; and (6) structural and
cognitive teratogenicity, including lower intelligent quotients, which
are most speciﬁcally associated with use of sodium valproate. These ef-
fects are not mutually exclusive. For example, valproate-related tremor
may be both idiosyncratic and dosage-related for an individual patient.
All AEDsmay potentially have adverse effects. Some of thesemay be
subtle, or may be only apparent retrospectively (i.e., after discontinuing
a particular drug after its long-term use). Behavioral and mood effects
may be particularly problematic in determining a true cause-and-
effect relationship. However, a careful analysis of the temporal relation-
ship between the onset or worsening of symptoms and the initiation of
a particular drug usually informs a reasonable clinical decision to either
continue or stop treatment. Not infrequently, AED choice is determined
by the presence of comorbid conditions for which a particular AEDmay
also be effective (e.g., migraine: topiramate and valproate; mood stabi-
lization: lamotrigine and valproate). Advances in pharmacogenomics
are beginning to yield clinical relevance. For example, carbamazepine
hypersensitivity may be predicted by the presence of the HLA-B*1502
allele in Han Chinese [210], and by that of the HLA-A*3101 allele in
Caucasians [211]. Further collaborative study in pharmacogenomics
(e.g., EpiPGX [212])may uncover other genomicmarkers to help predict
serious adverse effects and, thus, allow formore tailored and safer treat-
ment decisions for patients.
Valproate teratogenicity is now well-recognized, and is a signiﬁcant
limiting factor in prescribing valproate to women of child-bearing age.
This can pose difﬁcult risk–beneﬁt decision-making, particularly for
young women with idiopathic generalized epilepsy, and especially for
thosewithmore refractory disease. In addition, recent evidence is accu-
mulating that children born to mothers receiving sodium valproate are
more likely to experience learning difﬁculties and autistic spectrum dis-
orders compared with children exposed in utero to other AEDs, such as
carbamazepine, lamotrigine, and levetiracetam [213,214].
Some very effective AEDs are also limited by idiosyncratic adverse
drug reactions. For example, vigabatrin, which can be an effective drug
for a variety of epilepsies, may cause a peripheral retinopathy leading
to (an often asymptomatic) visual ﬁeld constriction in approximately
Fig. 2. Overview of antiepileptic drug treatment response.
Copyright © Pharmacogenomics. Reproduced with permission from Future Medicine, Ltd.
AED, antiepileptic drug; ADR, adverse drug reaction.
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used, especially in adult patients, including those with refractory dis-
ease whomay beneﬁt from therapy. Themechanism of this retinopathy
is unclear. It may have a pharmacogenomic basis, but studies to date
have been unrevealing [216].
6. Risks of nondrug treatments
6.1. Surgery
Surgery candidacy is a quantitative rather than a binary variable.
Risk–beneﬁt analysis for surgery includes not only the risks, but also
the realistic expectations (e.g., seizure freedom vs. seizure reduction).
For example, the risks associated with a temporal resection are greater
than the risks associated with neurostimulation. However, if the goal is
a seizure-free outcome, the analysis will favor surgery over
neurostimulation.
6.1.1. Resective surgery
Temporal lobe resections are the safest, with a serious complication
rate of b5%, and with continually improving techniques [217].
Nonlesional extra-temporal resections have a greater rate of complica-
tions and a lower rate of seizure freedom. Invasive EEG is often used
for extra-temporal resection, and that carries its own risks [218].
Lesional extratemporal resections are somewhere in-between. The
most frequent adverse effects of temporal lobe surgery are superior
quadrant visual ﬁeld defects (~8% for temporal lobectomies and rare
for selective resections), wound infections (~5%) [217], and mild verbal
memory declinewith dominant resections (~8%) [18]. These are usually
acceptable risks, given the probability of obtaining a seizure-free
outcome.
6.1.2. Corpus callosotomies
These are palliative (not aiming at seizure freedom), and are per-
formed for “drop seizures” and other severe motor seizures in refracto-
ry, symptomatic, generalized epilepsy. Surgical complications are rare
with two-phase surgeries (anterior two-thirds possibly followed by
the posterior third). The control of drop attacks with a callosotomycan be life- and injury-saving. Because these patients almost always
have major pre-existing neuropsychological deﬁcits, cognitive compli-
cations are generally minimal [219].6.1.3. Hemispherectomies
These are performed in young patients with severe epilepsy, usually
with hemispheric lesions and deﬁcits (hemiplegia and visual ﬁeld cuts).
Therefore, they are usually well-tolerated from a neurologic deﬁcit
point of view. Surgical complications, such as hydrocephalus, which
may necessitate a shunt, may occur. Rates and outcomes of surgical
complications have improved over time, with reﬁnements in tech-
niques, and use of functional rather than anatomic procedures [220]. A
seizure-freedom rate of 60%–65% is an important part of the risk–bene-
ﬁt analysis [221].6.2. Neurostimulation
6.2.1. Vagus nerve stimulation
Available in the United States since 1997, VNS typiﬁes the “low-risk,
low-reward” paradigm. As an extracranial procedure, VNS carries mini-
mal surgical risk and minor tolerability symptoms (i.e., hoarseness,
cough, voice change) during stimulation [222]. Infections of the genera-
tor or lead sites (as with any surgery) are possible but uncommon,
occurring in 3% to 5% of patients in one report [223]. Reports of arrhyth-
mias are also uncommon [223].6.2.2. Deep-brain stimulation
Deep-brain stimulation uses intracranial electrodes to stimulate
brain structures presumed to restrict seizure activity. The one and
only pivotal trial employed stimulation of the anterior nucleus of the
thalamus (N= 110), and no deathswere reported related to the device
or procedure. There were ﬁve reports of hemorrhage (none symptom-
atic), and 14 infections (none parenchymal — generator pocket, lead
track, burr hole, meningeal) [224]. Deep-brain stimulation is approved
in many countries but not in the United States.
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Responsive neurostimulation employs subdural and/or intrapa-
renchymal electrodes in a closed-loop approach to seizure control. The
device detects the onset of seizure activity in the implanted electrodes
and then sends back an electrical stimulation to the seizure focus. In a
pivotal trial (N = 191), no deaths related to the procedure or device oc-
curred. Five percent of patients experienced hemorrhage. None had per-
manent neurologic deﬁcit. There was a 5% infection rate (all of soft tissue
only), with 4 device explantations [225]. Responsive neurostimulation
was approved in November 2013 by the U.S. Food and Drug Administra-
tion and will likely become available elsewhere in the near future. Re-
sponsive neurostimulation has the capacity to treat two epileptogenic
foci, and provides useful diagnostic information as well, including docu-
mentation of seizures and onset sites.
Neurostimulation treatments may limit the availability of body
MRI once they are implanted, which is a disadvantage. Interestingly,
there are no dramatic differences in efﬁcacy between the three neuro-
stimulation treatments above, but the complications are greater for
the two intracranial techniques. At present, VNS may be the prefera-
ble option, by virtue of its risk–beneﬁt ratio. Opinions on the use of
neurostimulation techniques vary widely among Level-4 centers
[226,227].
6.3. Diet
The ketogenic, modiﬁed Atkins, and other related diets have been
shown to have some efﬁcacy in seizure reduction, with the ketogenic
diet being the most effective but the least well-tolerated. When used
properly, each has fairly minimal risks. Constipation, nausea, and other
gastrointestinal symptoms can occur initially. Nutritional deﬁciencies
may occur and necessitate the use of vitamin,mineral, and calcium sup-
plements. The ketogenic diet is more strict and, therefore, often used in
young children. The initial risks of dehydration and hypoglycemia are
mitigated by initiation in the hospital. Neither the ketogenic nor the
Atkins diets appear to signiﬁcantly increase long-term cardiovascular
risks. For seizures, they are usually used only for a short time. Late-
onset complications during maintenance therapy for chronic illness
can be monitored and avoided for the most part [228].
7. Conclusions
In presenting a treatment option, a clinician will typically review
with the patient the various pros and cons of the treatment. In epilepsy,
a physician typically discusses the probability of complete seizure con-
trol or signiﬁcant improvement versus the AE proﬁle associated with
the treatment. We believe that the risks of doing nothing or making
no changes are rarely discussed with patients, especially the conse-
quences of continued seizure activity, including the risks of mortality
andmorbidity. For patients with refractory epilepsy, the risks of contin-
ued seizuresmay outweigh the risks of treatments, including thosewith
possible serious adverse effects. Yet, in discussions with patients, those
treating epilepsy typically should balance the discussion between im-
proving seizure control and the potential for experiencing AEs. Highly
efﬁcacious epilepsy treatments associated with increased risks, such as
vigabatrin (vision loss) or felbamate (aplastic anemia), ormore invasive
procedures (callosotomy, DBS) are probably rarely discussed. As this re-
view clearly outlines, the risk of continuing seizures is associated with
signiﬁcantmortality andmorbidity and needs to be included in any dis-
cussion of treatment options. The risk of doing nothing or avoiding an
efﬁcacious treatment associated with an increased risk must be includ-
ed in the risk–beneﬁt discussion. Clearly, for some patients, the risk of a
potentially high-risk treatment is signiﬁcantly less than the risk of a po-
tential AE fromongoing seizures. Clinicians need to include assessments
of loss of life, quality of life, and epilepsymorbidities as part of any treat-
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